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Abstract: Background: The aim of this study was to investigate the effect of lower urinary tract
symptoms (LUTS) on behavior related to treatment of Polish adults aged ≥ 40 years. Methods: We
conducted a computer-assisted telephone survey with a study sample stratified by age, sex, and
place of residence (type, size, urban versus rural) reflecting the entire Polish population. Participants
rated the frequency and symptom-specific bother of individual LUTS and their effects on seeking and
receiving treatment, treatment satisfaction, and treatment continuation. We adjusted multiple logistic
regression models to analyze the simultaneous effects of predictor variables on each dependent
variable. Results: Overall, 6005 participants completed the interview. One third (29.6–33.5%) of
participants with LUTS were seeking treatment, and 24.0–26.4% received treatment. There was
no difference in treatment seeking and receiving between urban and rural areas. Whereas storage
and voiding symptoms were significantly related to treatment seeking by both men and women,
treatment receiving correlated only with voiding symptoms in men and only with storage symptoms
in women. Most respondents who received treatment were satisfied; treatment dissatisfaction was
related to the presence of storage symptoms in both men and women. Only 50% of all participants
continued their treatment; discontinuation of treatment was statistically more prevalent for women
than for men. Conclusion: This investigation, the first population-representative study performed in
Eastern Europe, revealed a low frequency of seeking treatment for LUTS. In addition, symptoms that
inclined participants to seek treatment might not have been adequately addressed by the treatment
they received. We also found a relatively high rate of treatment discontinuation. Clearly, there is a
need for both improved patient education about LUTS treatment and a need for increased clinician
awareness of the coexistence of different symptoms in men and women plus proactive evaluation by
physicians for all types of LUTS and associated bother.
Keywords: Poland; LUTS; OAB; epidemiology; treatment seeking
1. Introduction
Lower urinary tract symptoms (LUTS) include storage, voiding, and post-micturition
symptoms [1]. The prevalence of LUTS has been reported in some large-scale population-
based analyses. LUTS were found to affect up to 74% of adults aged ≥ 40 years in Europe
and North America [2], 75% in South America [3], and 61% in Asia [4]. In a recent
population-representative epidemiological study of LUTS in Poland, the first reliable and
nationwide epidemiological study of LUTS in an Eastern European country, we reported
LUTS prevalence of 69.8% in adults aged ≥ 40 years, with more women affected than men
(72.6% vs. 66.2%) [5].
Although not considered life-threatening, LUTS can be highly bothersome and can
negatively affect social functioning, mental health, sleep, sexuality, productivity, and
overall quality of life [6]. However, individuals have many concerns that prevent them
from seeking help. Studies of barriers to seeking treatment have pointed to embarrassment,
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anxiety, social stigma, or acceptance of LUTS as an unavoidable aspect of aging [7]. Often,
people are simply unaware that there may be treatment for their ailment [8]. It is important
to know which LUTS and symptom-related bothers prompt men and women to seek
treatment because these data would be valuable in adjusting treatment approaches. This
knowledge may also support health improvement programs, educational campaigns, and
resource allocation.
Whereas healthcare-related behaviors for LUTS have been investigated in Western
Europe and some other regions of the world, there are no data for countries of Central and
Eastern Europe [8]. Moreover, most studies that have examined the effects of symptoms
and symptom-specific bother on healthcare-related behaviors have been conducted for
patient-based samples; data for the general population are especially sparse, regardless of
the region of the world. Because some local cultural norms such as lifestyle factors may
inhibit individuals from admitting or discussing their health issues, the healthcare-related
behaviors may also vary between countries and regions [2,9]. Indeed, Central-Eastern Eu-
rope is often considered a distinct cultural entity [10]. As Slavic people, Poles are culturally
different from other European people, particularly Germanic and Romance people [11]. Ad-
ditionally, with a relatively high number of people living in Polish rural regions, available
data on behavior related to LUTS treatment may not be fully transferable to Poland because
relationships between LUTS and treatment-related behavior have not been reported and
compared between urban and rural areas. Therefore, the aim of this study was to analyze
the effect of LUTS on treatment seeking, treatment receiving, treatment satisfaction, and
treatment continuation, in a representative group of men and women aged ≥40 years in
Poland, the largest country by land area in Central Europe and the third most populous
country in Eastern Europe [12–14].
2. Materials and Methods
This was a population-based and cross-sectional study performed in Poland. The
goal was to examine the prevalence and symptom-specific bother of LUTS and to evaluate
the impact of these symptoms on behavior related to treatment. The study included
representative pools of men and women aged ≥ 40 years living in all geographical regions
of Poland (including urban and rural areas with appropriate proportions). We described
the justification for this recruitment approach and the details of the survey and study
design elsewhere [5]. The Ethics Committee of Jagiellonian University Medical College,
Krakow, Poland (1072.6120.160.2019) approved the study. The study is registered with
ClinicalTrials.gov (NCT04121936).
A computer-assisted telephone survey was conducted between 1 September and
30 December 2019. We used the most recent census and a sample-matching method to
create a target sample [15]. Either before or after completion of the questionnaires, we
stratified the survey sample by age, sex, and place of residence (for both geographical
regions, i.e., 16 states = voivodships, and type/size of living places, including an adequate
proportion of urban and rural areas) to reflect the entire Polish population. We excluded
participants with current/past urinary tract infection (within one month), women pregnant
at the time of the survey, and women who had given birth within the preceding six months.
All participants reported the demographics and presence of LUTS, as recommended
by the International Continence Society (ICS), which encompassed frequency, urgency,
urgency with fear of leaking, nocturia, urinary incontinence (urgency, stress, mixed, leak
for no reason), intermittency, slow stream, splitting/spraying, hesitancy, terminal dribble,
straining, incomplete emptying, and post-micturition dribble [1]. The International Prostate
Symptom Score (IPSS) [16] and the Overactive Bladder-Validated 8-question Screener (OAB-
V8) [17] were also used. All terms and instruments were adapted, validated, and presented
in Polish.
Participants graded the frequencies of experiencing individual LUTS during the prior
month; ratings were based on a Likert-like scale: none (score 0), less than 1 in 5 times (score 1),
less than half the time (score 2), about half the time (score 3), more than half the time (score
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4), or almost always (score 5). For frequencies of at least “less than 1 in 5 times”, participants
were also asked about the degree of associated bother by the particular LUTS and scored:
not at all (score 0), a little bit (score 1), somewhat (score 2), quite a bit (score 3), a great deal
(score 4), or a very great deal (score 5). Table 1 enumerates the telephone survey questions
pertaining to treatment seeking, treatment receiving, satisfaction, and continuation.
Table 1. Questions regarding treatment seeking, treatment receiving, treatment methods used,
treatment satisfaction, and treatment continuation.
Symptoms: frequency, urgency, urgency with fear of leaking, nocturia, urinary incontinence
(urgency, stress, mixed, leak for no reason), intermittency, slow stream, hesitancy, straining,
splitting/spraying, terminal dribble, incomplete emptying, post-micturition dribble
1. Have you sought medical attention for your urinary or bladder problems?
Yes/No
2. Have you received any treatment for your urinary or bladder problems?
Yes/No
3. Which of the following methods of treatment did you use?
Lifestyle changes/Exercise and physiotherapy/Non-prescription drugs/Prescription
drugs/Surgical treatment
4. Do you continue the treatment?
Yes/No
5. Are/Were you satisfied with the treatment?
Yes/No
To make our results comparable to other epidemiological analyses of LUTS, we used
two definitions for LUTS prevalence: definition I, symptoms occurring less than half the
time or more, and definition II, symptoms occurring half the time or more [2,3].
Statistics
We used the Pearson chi-squared test to assess correlations of categorical variables.
We adapted several logistic regression models to measure concurrent effects of predictor
variables on dichotomous dependent variables (treatment seeking, treatment receiving,
satisfaction, and continuation). The predictor variables we considered were age, sex,
education, employment, marital status, urban or rural residence, frequency, and bother
of each LUTS. For regression analysis, occurrence of a particular LUTS was considered
established when the LUTS was experienced less than half the time or more (i.e., IPSS
grade ≥ 2); bother was considered to exist when it was rated somewhat or greater (equal
to OAB-V8 grade ≥ 2).
The group of variables was large; thus, we chose predictor variables for each model
when the association of the predictor variables with the dependent variable reached 20%
significance in univariate analysis. Initially, we included all selected variables; then,
we sequentially eliminated variables with < 5% significance (except for age, the control
variable) in the order of their significance (backward method). We separately adjusted
models for men and women. All the data were analyzed with SPSS Statistics software (IBM
Corporation, Armonk, NY, USA, version 24.0).
3. Results
3.1. Treatment Seeking and Treatment Receiving
Among a group of respondents with symptoms that occurred less than half the time
or more (definition I), 29.6% (n = 1239) were seeking treatment and 24% (n = 1004) received
treatment (Table 2).
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Table 2. Treatment-related behaviors.
Sex Place of Living
Men Women Urban Rural Total
n % n % n % n % n %
Men and women with symptoms occurring less than half the time or more (definition I) ˆ
Treatment seeking 541 31.3 698 28.4 776 30.1 463 28.8 1239 29.6
Treatment receiving 441 25.5 563 22.9 634 24.6 370 23.0 1004 24.0
Treatment satisfaction 378 * 85.7 444 78.9 511 80.6 311 84.1 822 81.9
Treatment dissatisfaction 63 14.3 119 21.1 123 19.4 59 15.9 182 18.1
Treatment continuation 332 ** 75.3 197 35.0 340 53.6 189 51.1 529 52.7
Treatment discontinuation 109 ** 24.7 366 65.0 294 46.4 181 48.9 475 47.3
Treatment satisfaction with continuation 275 ** 62.4 154 27.4 272 42.9 157 42.4 429 42.7
Treatment satisfaction with discontinuation 103 ** 23.4 290 51.5 239 37.7 154 41.6 393 39.1
Treatment dissatisfaction with continuation 57 12.9 43 7.6 68 10.7 32 8.6 100 10.0
Treatment dissatisfaction with
discontinuation 6 * 1.4 76 13.5 55 8.7 27 7.3 82 8.2
Men and women with symptoms occurring at least half the time (definition II) ˆ
Treatment seeking 457 * 37.9 556 30.6 631 33.7 382 33.2 1013 33.5
Treatment receiving 373 * 30.9 427 23.5 497 26.5 303 26.3 800 26.4
Treatment satisfaction 298 * 79.9 308 72.1 367 73.8 239 78.9 606 75.8
Treatment dissatisfaction 75 20.1 119 27.9 130 26.2 64 21.1 194 24.2
Treatment continuation 284 ** 76.1 165 38.6 282 56.7 167 55.1 449 56.1
Treatment discontinuation 89 ** 23.9 262 61.4 215 43.3 136 44.9 351 43.9
Treatment satisfaction with continuation 230 ** 61.7 124 29.0 217 43.7 137 45.2 354 44.3
Treatment satisfaction with discontinuation 68 * 18.2 184 43.1 150 30.2 102 33.7 252 31.5
Treatment dissatisfaction with continuation 54 14.5 41 9.6 65 13.1 30 9.9 95 11.9
Treatment dissatisfaction with
discontinuation 21 5.6 78 18.3 65 13.1 34 11.2 111 13.9
ˆ Based on definition I, prevalence of LUTS was 69.8% (men: 66.2%; women 72.6%). Based on definition II, prevalence of LUTS was 50.4%
(men: 46.2%; women: 53.5%). * p < 0.05 between men and women. ** p < 0.01 between men and women.
For respondents with symptoms that occurred half the time or more (definition II),
33.5% (n = 1013) were seeking treatment, and, again, many of these persons received
treatment (26.4%; n = 800). On the basis of definition II, we found that statistically more
men than women sought and received treatment (Table 2). This trend was also hinted at
with definition I; however, it was not statistically significant. We did not find differences in
looking for treatment and treatment received between individuals who resided in urban
and rural areas.
Men with bother associated with urgency, frequency, slow stream, hesitancy, and
incomplete emptying were more likely to seek treatment compared with men without these
symptoms (Table 3).
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Table 3. Heat map of logistic and ordered multiple regressions for treatment seeking, treatment receiving, dissatisfaction,
and discontinuation by men and women. Numbers show adjusted odd ratios (95% confidence interval). Red cells indicate
an increase and blue cells indicate a decrease in the likelihood of treatment seeking, treatment receiving, dissatisfaction, or
discontinuation. Blank cells indicate that there was not a statistically significant relationship.
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Women bothered by urgency, frequency, urgency urinary incontinence, intermittency,
and straining were more likely to seek treatment than women without these symptoms.
We investigated an increase in the likelihood of treatment seeking for LUTS with each
additional year of age for both sexes; for men, an increase of 7% in seeking treatment
with each successive year and, for women, an increase of 3% per year (p < 0.01). For
men, the chance of seeking treatment for LUTS was higher for persons married or living
with a partner.
The most frequent treatment was prescription drugs (definition I: 70%; definition II:
69.4%) followed by over-the-counter drugs (26.1%; 23%), physiotherapy (19.6%; 19.9%),
surgery (17%; 18.3%), and lifestyle changes (14.7%; 15.3%). One-third of respondents
(definition I: 32.4%; definition II: 32.1%) received combined treatment, i.e., at least two of
the aforesaid treatment methods.
Men bothered by intermittency, straining, and incomplete emptying were more
likely to have been receiving treatment compared with men who lacked the symptoms
(Table 3). Women with urgency with fear of leaking and bothersome frequency were
more likely to receive treatment relative to women without those symptoms. Both men
and women experienced yearly increases in the likelihood of receiving treatment for
LUTS (an increase of 10% per year for men and 6% for women; p < 0.01).
3.2. Treatment Satisfaction
Significantly more men than women were satisfied with the treatment they received
(definition I: 85.7% vs. 78.9%; definition II: 79.9% vs. 72.1%; Table 2). Consequently,
more women than men were dissatisfied with the treatment (definition I: 21.1% vs. 14.3%;
definition II: 27.9% vs. 20.1%). There was no influence of urban versus rural status on
treatment satisfaction.
Men bothered by urgency incontinence, urgency with fear of leaking, and frequency
and women bothered by urgency incontinence, urgency with fear of leaking, frequency,
and incomplete emptying had a higher risk of treatment dissatisfaction compared with
individuals lacking these symptoms (Table 3). For women, there was a 5% yearly reduction
in risk of treatment dissatisfaction (p < 0.01).
3.3. Treatment Continuation
More men than women reported continuation of treatment (definition I: 75.3% vs.
35%; definition II: 76.1% vs. 38.6%; Table 2); thus, women were more likely to discontinue
treatment (definition I: 65.0% vs. 24.7%; definition II: 61.4% vs. 23.9%). The decision to
continue or discontinue treatment was not affected by urban versus rural status.
Men with slow stream and bothersome post-micturition dribble had a lower risk of
treatment discontinuation compared with men lacking those symptoms (Table 3). Con-
versely, men with incomplete emptying had a higher risk of stopping treatment. Women
bothered by leak for no reason were at greater risk of treatment cessation compared with
women without this symptom.
3.4. Combination Relationships
A combination of treatment satisfaction and treatment continuation was statistically
more prevalent in men than women, regardless of the LUTS prevalence definition (Table 2).
Conversely, women were more likely to discontinue their satisfied treatment (definition I:
51.5%) compared with men (definition I: 23.4%). Dissatisfied women were also more likely
to stop their treatment (definition I: 13.5%) compared with men (definition I: 1.4%).
4. Discussion
This investigation is the first large population-based study performed in Eastern
Europe that analyzed the scope of patient preferences for treatment for LUTS. The study
included all geographical regions of Poland, urban and rural, and provides reliable, valid,
and consistent information of LUTS prevalence and behavior related to treatment. Al-
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though LUTS were highly prevalent in individuals aged ≥ 40 in Poland, less than one-third
of people affected by LUTS pursued treatment.
The low percentage of people with LUTS who sought treatment has been reported
elsewhere. The Epidemiology of Lower Urinary Tract Symptoms (EpiLUTS) study, an
Internet-based population inquiry in Sweden, the USA, and the UK determined that only
29% of men and 28% of women affected by LUTS sought treatment for bladder problems [8].
In Asia, an Internet survey with participants from South Korea, Taiwan, and China showed
that 26% of respondents with any LUTS reported visiting healthcare professionals because
of their LUTS [4]. The Brazil LUTS, a telephone interview conducted in five major cities
of Brazil, documented that up to 30.6% of respondents with LUTS sought treatment [18].
Our observation of treatment seeking by 29.6% of adults in Poland who reported LUTS
is broadly comparable with the foregoing population-based studies. Therefore, the poor
attention to health by individuals with LUTS is a significant, global concern.
We need to reflect on several shared pathways that restrain people from seeking
help. First, LUTS can cause embarrassment, thereby inhibiting the search for medical help.
Qualitative study findings suggest that these issues are worsened by apprehension even to
seek reassuring environments to discuss delicate matters with healthcare professionals [19].
Second, there is still considerable belief that LUTS are a “natural” part of aging. People with
LUTS may be perceived by themselves and by their partners and families as being frail and
aged [7]. Third, the public is mostly unaware that LUTS can be treated with consequent
improvement in the quality of life [20]. Some people consider LUTS to be incurable
or untreatable, whereas others have concerns about the financial costs or the adverse
effects of treatment (e.g., side effects of medication) [21]. Without adequate information
about treatment, individuals cannot take optimal action for treatment seeking. Clearly,
education is a crucial factor for treatment seeking. An individual’s understanding of LUTS
can affect motivation and adherence, which can influence the treatment outcome [22].
Importantly, education and counseling of LUTS can be provided by a variety of clinicians,
such as physicians (including multiple professions, e.g., urologists, gynecologists, general
practitioners, geriatrists), nurses, and, in some cases, physiotherapists specialized in pelvic
floor physiotherapy.
In our study, bother related to symptoms in distinct categories, i.e., storage (for
men: frequency, urgency; for women: frequency, urgency, urgency urinary incontinence),
voiding (for men: slow stream, hesitancy; for women: intermittency, straining), and post-
micturition (for men: incomplete emptying), was correlated with a higher likelihood
of seeking treatment. These data support the concept that voiding symptoms are not
the only LUTS of men and that storage symptoms are not the only LUTS of women
because men and women looked for treatment regardless of the LUTS subgroup. Therefore,
the norm in routine clinical practice should be a broad and symptom-driven approach
wherein LUTS are not disease- or condition-specific. In addition, despite being commonly
related to bladder outlet obstruction, LUTS may be indicative of bladder dysfunction
and other structural and/or functional abnormalities of the urinary tract; therefore, LUTS
may herald many non-urological conditions [23]. Thus, for effective and individualized
treatment, patients with symptoms from multiple categories need extensive and thorough
diagnostic evaluation with a holistic approach for their LUTS. We found that more men than
women sought treatment for LUTS, a phenomenon that coincided with other international
studies that reported men were more likely to initiate conversations with clinicians [24,25].
Nevertheless, clinicians still need a proactive attitude toward both men and women.
Most participants seeking treatment received it. For men, only intermittency, straining,
and incomplete emptying were correlated with relatively greater reception of treatment.
However, these symptoms are only voiding and post-micturition that physicians commonly
associate with benign prostatic hyperplasia. As both frequency and urgency were related to
treatment seeking by men, and these symptoms did not correlate with receiving treatment,
storage symptoms may represent an unmet need. Conversely, in women, only those with
urgency with fear of leaking and frequency were more likely to receive treatment, even
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though intermittency and straining were related to treatment seeking. Therefore, it appears
that physicians considered only storage symptoms in their treatment plans for women.
Thus, we hypothesize that not only patients but also clinicians, non-urologists in particular,
should be adequately educated about LUTS diversity and coexistence, their comprehensive
evaluation, and various treatment methods.
These unmet needs have additional implications. We found that men with bother
from frequency, urgency with fear of leaking, and urgency incontinence were more likely
to be dissatisfied with their treatment. Because storage symptoms in men correlated
with treatment seeking but were not associated with receiving treatment, persisting with
ineffective/inadequate overall management in men may have a profound negative impact
on treatment satisfaction. Control of storage symptoms is often unsatisfactory in men
with treatment only for voiding symptoms, i.e., with alpha-blockers or 5-alpha-reductase
inhibitors. Anticholinergics or agonists of the beta-3 receptor are recommended as a first-
line therapy for storage symptoms associated with overactive bladder. However, clinicians
may refrain from prescribing antimuscarinics because of unfounded notions that they
promote urinary retention [26]. The European Association of Urology recommends a
combination of an alpha-blocker with an antimuscarinic for men with moderate or severe
LUTS, provided that risk factors for progression of benign prostatic hyperplasia are absent
and that alpha-blocker monotherapy is insufficient to relieve storage symptoms [23].
For women, treatment dissatisfaction was statistically higher for urgency with fear
of leaking and urgency urinary incontinence, although storage symptoms correlated with
both treatment seeking and treatment receiving. This difference may result from storage
symptoms being poorly controlled. In instances of ineffective treatment, the European
Association of Urology recommends considering dose escalation or offering an alterna-
tive antimuscarinic formulation, or mirabegron, or a combination [27]. Notably, in recent
international studies, mirabegron was associated with a significantly longer time to discon-
tinuation, greater persistence, and better adherence than achieved with antimuscarinics [28].
Treatment dissatisfaction of women also correlated with incomplete emptying, which may
be one of the symptoms of pelvic organ prolapse. This finding may further highlight that
LUTS are not related to only dysfunctions of the bladder–sphincter complex. Unsatisfied
treatment for LUTS requires thorough investigation of LUTS origin and sometimes close
cooperation between urologists and gynecologists.
Patients discontinue LUTS treatment at high rates [28]. In our study, statistically
more women than men discontinued their treatments. This observation may be explained
in two different ways. Whereas treatment for LUTS in men typically includes alpha-
blockers or 5-alpha-reductase inhibitors with mild side effect profiles, treatment of LUTS
in women often includes anticholinergics, with significant dropouts because of adverse
events [29]. Alternatively, until now, public urological campaigns in Poland have been
focused mainly on men, and women might be inadequately targeted. Thus, we speculate
that men in Poland may be better educated about LUTS. Regardless, in Poland, future
health-improvement programs in functional urology must reach men and women.
Increasing age had effects on treatment seeking and treatment receiving by men and
women, but this correlation was more evident for men (7–10% increase with each additional
year of age) than women (3–6% yearly increase). We also found a 5% reduction in treatment
dissatisfaction by women for each additional year of age, but no such trend was evident for
men. Corresponding findings have been reported in some previous studies [8,24]. Some
experts account for this difference by noting that women usually start earlier than men
with a routine of frequent healthcare visits [18].
We did not find differences between urban and rural status in treatment-related
behaviors. Before conducting the study, we hypothesized that people from urban areas
would be more active in treatment seeking compared with people from rural regions. This
hypothesis emerged from a report that people in rural areas in Poland were more hesitant to
admit or discuss their health issues [30]. However, the data for that conclusion are decades
old. Since 2004, Poland has been a member of the European Union, the organization that
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initiated and funded several large health improvement programs in Polish rural areas [31].
Even without longitudinal analyses of this correlation, with our results, we hypothesize
that the health differences between rural and urban areas in Poland are beginning to blur.
Further, the growing population density in Poland is leading to the merging of urban and
rural areas [31].
This study was limited by the fact that persons self-reported LUTS and treatment.
Cold-calling particularly limits assessment of treatment continuation and discontinuation.
This concern is important with respect to patients who received surgical treatment. Al-
though surgical treatment for LUTS (e.g., implantation of midurethral sling in women
or transurethral resection of prostate in men) is successful in most cases, some patients
may not benefit from surgery, and surgical treatment for LUTS may not be definitive.
Further, some treatment options may be adjusted after surgery (e.g., reprogramming of
pulse generator after electrode implantation in sacral neuromodulation) or treatments may
require repetition (e.g., injections of onabotulinumtoxinA or bulking agents). We must also
remember that some patients treated with surgery may also receive other treatments and
they might continue or discontinue the nonsurgical interventions. With a cross-sectional
design, at the time of interview, some respondents might have been awaiting scheduled
surgery. Therefore, we could not rigidly qualify patients who received surgery as either
continuing or discontinuing treatment; instead, we asked the respondents an open question
regarding their overall treatment status (i.e., continuation or discontinuation). Contrary
to clinic-based studies, estimation of treatment continuation or discontinuation for LUTS
at the population level is more difficult, and there is no perfect standard measure for this
parameter in studies such as ours. Nonetheless, the approach we adopted has been used in
other large-scale population-based studies that analyzed LUTS and treatment behaviors
related to LUTS [3,4,8,32]. We designed our methodology to enable comparisons of our
results with other populations. We needed to provide results for the entire population in
order to make available estimates that attract interdisciplinary frameworks for national
health improvement programs with appropriate allocation of resources by governments
and healthcare systems. However, the need for population estimates required some gen-
eralizations (e.g., merging conservative, pharmacological, and surgical treatments). In
addition, we did not collect data concerning barriers to healthcare-seeking and drug-related
adverse effects.
5. Conclusions
Although LUTS were highly prevalent in Poland, the degree of treatment seeking was
low. The occurrence of symptoms from all three ICS symptom groups (storage, voiding,
post-micturition) and the related bother were correlated with treatment-related outcomes,
including treatment seeking, treatment receiving, treatment satisfaction, and/or treatment
continuation. We observed these relationships with men and women. Clearly, there is a
need to educate the general Polish population about potential benefits of LUTS treatment.
In addition, it is incumbent upon physicians to proactively inquire with patients about
LUTS and comprehensively assess multiple/various symptoms and, especially, associated
bother.
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